References
- LiQEpidemiology of human infections with avian influenza A(H7N9) virus in ChinaN. Engl. J. Med.2014370 520 53210.1056/NEJMoa1304617
- World Health Organization. Human infection with avian influenza A(H7N9) virus—China. 2017 http://www.who.int/csr/don/5-september-2017-ah7n9-china/en/. Accessed 20 July 2017.
- CouchRBPatelSMWadebowersCLNiñoDA randomized clinical trial of an inactivated avian influenza A (H7N7) vaccinePLoS ONE20127e4970410.1371/journal.pone.00497043519847
- JacksonLAEffect of varying doses of a monovalent H7N9 influenza vaccine with and without AS03 and MF59 adjuvants on immune response: a randomized clinical trialJ. Am. Med. Assoc.201531423724610.1001/jama.2015.7916
- MadanAImmunogenicity and safety of an AS03-adjuvanted H7N9 pandemic influenza vaccine in a randomized trial in healthy adultsJ. Infect. Dis.20162141717172710.1093/infdis/jiw4145144728
- PiresAFortunaAAlvesGFalcãoAIntranasal drug delivery: how, why and what for?J. Pharm. Pharm. Sci.20091228831110.18433/J3NC79
- World Health Organization. FDA clears first quadrivalent flu vaccine. 2012 http://www.who.int/influenza_vaccines_plan/news/news_digest_2012/en/index9.html. Accessed 15 July 2017.
- ChenZDevelopment of a high-yield live attenuated H7N9 influenza virus vaccine that provides protection against homologous and heterologous H7 wild-type viruses in ferretsJ. Virol.2014887016702310.1128/JVI.00100-144054345
- NeutraMRKozlowskiPAMucosal vaccines: the promise and the challengeNat. Rev. Immunol.2006614815810.1038/nri1777
- MaFZhangQZhengLInterleukin/chitosan (JY) adjuvant enhances the mucosal immunity of human papillomavirus 16 L1 virus-like particles in miceBiotechnol. Lett.20153777377710.1007/s10529-014-1739-3
- RiesePSakthivelPTrittelSGuzmánCAIntranasal formulations: promising strategy to deliver vaccinesExpert Opin. Drug Deliv.20141111610.1517/17425247.2014.931936
- WangZBThe mechanism of action of acid-soluble chitosan as an adjuvant in the formulation of nasally administered vaccine against HBVRSC Adv.20166967859679710.1039/C6RA14419E
- SlutterBNasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigenVaccine2010286282629110.1016/j.vaccine.2010.06.121
- LiaoWLinJXLeonardWInterleukin-2 at the crossroads of effector responses, tolerance, and immunotherapyImmunity201338132510.1016/j.immuni.2013.01.0043610532
- HarandiAMSanchezJErikssonKHolmgrenJRecent developments in mucosal immunomodulatory adjuvantsCurr. Opin. Investig. Drugs20034156161
- GluckRSafety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvantJ. Infect. Dis.20001811129113210.1086/315337
- Van GinkelFWJacksonRJYukiYMcgheeJRCutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissuesJ. Immunol.20001654778478210.4049/jimmunol.165.9.4778
- DodaneVKhanMAMerwinJREffect of chitosan on epithelial permeability and structureInt. J. Pharm.1999182213210.1016/S0378-5173(99)00030-7
- KangMLIn vivo induction of mucosal immune responses by intranasal administration of chitosan microspheres containing Bordetella bronchiseptica DNTEur. J. Pharm. Biopharm.20066321522010.1016/j.ejpb.2006.01.010
- VicenteSCo-delivery of viral proteins and a TLR7 agonist from polysaccharide nanocapsules: a needle-free vaccination strategyJ. Control Release201317277378110.1016/j.jconrel.2013.09.012
- HuaYDNA vaccine encoding central conserved region of G protein induces Th1 predominant immune response and protection from RSV infection in miceImmunol. Lett.20161799510110.1016/j.imlet.2016.09.011
- TafaghodiMHepatitis B surface antigen nanoparticles coated with chitosan and trimethyl chitosan: impact of formulation on physicochemical and immunological characteristicsVaccine2012305341534810.1016/j.vaccine.2012.06.035
- McginnesLWAssembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteinsJ. Virol.20118536637710.1128/JVI.01861-10
- KyriazisIDThe leishmanicidal activity of oleuropein is selectively regulated through inflammation- and oxidative stress-related genesParasit. Vectors2016944110.1186/s13071-016-1701-44977900
- WidjojoatmodjoMNRecombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton ratsVaccine2015335406541410.1016/j.vaccine.2015.08.056
- VikasRDevelopment and characterization of mucoadhesive HBsAg PLGA microsphere for nasal vaccine deliveryDrug Deliv.201611113122
- Kumar, P. et al. High-throughput detection method for influenza virus. J. Vis. Exp. 60, e3623 (2012).
- SmithGEDevelopment of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virusVaccine2013314305431310.1016/j.vaccine.2013.07.043
- KlausbergerMOne-shot vaccination with an insect cell-derived low-dose influenza A H7 virus-like particle preparation protects mice against H7N9 challengeVaccine20143235536210.1016/j.vaccine.2013.11.0363906608
- YunNEInjectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1)Virology200837419820910.1016/j.virol.2007.12.0292680697
- TakahashiEAttenuation of inducible respiratory immune responses by oseltamivir treatment in mice infected with influenza A virusMicrobes Infect.20101277878310.1016/j.micinf.2010.04.013